|
A1: no patient specific details have been provided.Therefore, the patient initials reflect the w.L.Gore internal case number.W.L.Gore & associates, inc.(gore) is submitting this report to comply with 21 c.F.R.Part 803, the medical device reporting regulation.This report is based upon information obtained by gore, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Blank fields present on this report include required fields and fields determined to be not applicable.Blank required fields indicate that the information was not provided, was deemed unavailable or was not applicable.This report does not constitute an admission or a conclusion by fda, gore, or its associates that the device, gore or its associates caused or contributed to the event described in the report.In particular, this report does not constitute a legal admission by anyone that the product described in this report has any defects or has malfunctioned, as defined from a legal standpoint.These words are included in the report and are fixed items for selection created by the fda, to categorize the type of event solely for the purpose of reporting pursuant to part 803.This statement should be included with any information or report disclosed to the public under the freedom of information act.
|
|
It was reported to gore that on (b)(6) 2026, the patient underwent transcatheter aortic valve implantation (tavi) using the gore® dryseal flex introducer sheath as an accessory.After insertion of the 18fr sheath into the patient, blood leakage from the dryseal valve was observed upon removal of the dilator.As the bleeding continued, the device was replaced with an alternative, and the procedure was continued.No hemodynamic deterioration or blood transfusion attributable to this bleeding was reported.The patient tolerated the procedure.
|